Glucose Homeostasis, Hypoglycemia, and the Burnt-Out Diabetes Phenomenon in Kidney Disease

Glucose Homeostasis, Hypoglycemia, and the Burnt-Out Diabetes Phenomenon in Kidney Disease

Chronic kidney illness (CKD) is amongst the most prevalent and dire problems of diabetes mellitus in adults throughout the world. Diabetes considerably contributes to the burden of kidney illness, such that one third to at least one half of CKD in the United States and many different international locations is attributable to diabetic kidney illness (DKD). As DKD progresses to end-stage renal illness (ESRD), sufferers are at heightened danger for atypical glycemic problems, together with the improvement of burnt-out diabetes, manifested by hypoglycemic bouts and poor outcomes.
Furthermore, even in the absence of diabetes, hypoglycemia is a frequent incidence in CKD sufferers which will contribute to their excessive burden of heart problems and demise. Extrapolation of knowledge from scientific trials in high-cardiovascular-risk populations and observational research in sufferers with non-dialysis-dependent (NDD) CKD and ESRD recommend that reasonable glycemic targets outlined by glycated hemoglobin ranges of 6% to eight% and glucose ranges of 100 to 150 mg/dL are related to higher survival in DKD sufferers.
However, given the imprecision of glycated hemoglobin ranges in kidney illness, additional analysis is required to find out the optimum glycemic metric and goal in diabetic NDD-CKD and ESRD sufferers. Given their exceedingly excessive cardiovascular morbidity and mortality, there’s a compelling want for additional investigation of the way to optimally handle dysglycemia in the NDD-CKD and ESRD populations.

Dendritic Integration Dysfunction in Neurodevelopmental Disorders

Neurodevelopmental issues (NDDs) that have an effect on cognition, social interplay, and studying, together with autism spectrum dysfunction (ASD) and mental incapacity (ID), have a powerful genetic element. Our present understanding of danger genes highlights two most important teams of dysfunction: these in genes that act as chromatin modifiers and these in genes that encode for proteins localized at or close to synapses. Understanding how dysfunction in these genes contributes to phenotypes noticed in ASD and ID stays a serious query in neuroscience.
In this overview, we spotlight rising proof suggesting that dysfunction in dendrites – areas of neurons that obtain synaptic enter – could also be key to understanding options of neuronal processing affected in these issues. Dendritic integration performs a basic function in sensory processing, cognition, and acutely aware notion, processes hypothesized to be impaired in NDDs. Many high-confidence ASD genes perform inside dendrites the place they management synaptic integration and dendritic excitability.
Further, growing proof demonstrates that a number of ASD/ID genes, together with chromatin modifiers and transcription components, regulate the expression or scaffolding of dendritic ion channels, receptors, and synaptic proteins. Therefore, we talk about how dysfunction of subsets of NDD-associated genes in dendrites results in defects in dendritic integration and excitability and could also be one core phenotype in ASD and ID.
 Glucose Homeostasis, Hypoglycemia, and the Burnt-Out Diabetes Phenomenon in Kidney Disease

In vitro dissolution concerns related to nano drug supply techniques

Nano drug supply techniques (NDDS) supply promising answer for the translation of future nanomedicines. As bioavailability and therapeutic outcomes may be improved by altering the drug launch from these NDDS, it turns into important to completely perceive their drug launch kinetics. Moreover, U.S. Food and Drug Administration requires essential analysis of potential security, efficacy, and public well being impacts of nanomaterials. Spiraling up market share of NDDS has additionally stimulated the pharmaceutical trade to develop their cost-effective generic variations after the expiry of patent and related exclusivity.
However, in contrast to the standard dosage types, the in vivo disposition of NDDS is very intricate and totally different from their in vitro habits. Significant challenges exist in the institution of in vitro-in vivo correlation (IVIVC) attributable to incomplete understanding of nanoparticles’ in vivo biofate and its influence on in vitro experimental protocols. A rational design of dissolution might function high quality and amount management instrument and assist develop a significant IVIVC for favorable financial implications. Clinically related drug product specs (essential high quality attributes) may be recognized by establishing a hyperlink between in vitro efficiency and in vivo publicity.
In vitro dissolution can also play a pivotal function to know the dissolution-mediated clearance and security of NDDS. Prevalent in vitro dissolution strategies for NDDS and their limitations are mentioned in this overview, amongst which USP four is gaining extra curiosity lately. Researchers are working diligently to develop biorelevant in vitro launch assays to make sure optimum therapeutic efficiency of generic variations of those NDDS. This article focuses on these research and presents vital concerns for the future improvement of clinically related in vitro launch strategies.

A overview of the proof on the danger of congenital malformations and neurodevelopmental issues in affiliation with antiseizure medicines throughout being pregnant

IntroductionThe majority of ladies with epilepsy require remedy with antiseizure medicines (ASM) all through being pregnant. However, in utero publicity to a number of ASM has been related to an elevated danger of congenital malformations and/or neurodevelopmental issues (CM/NDD) in the baby, however observational proof is methodologically heterogeneous.Areas coatedWe critically consider present proof on the danger of CM/NDD in youngsters of ladies with epilepsy after in utero publicity to totally different ASM.
We spotlight traits of various information sources and talk about their advantages and drawbacks. This overview consists of proof revealed earlier than December 2020 (non-systematic literature search).Expert opinionGiven the lack of randomized managed trials, proof on in utero security of ASM originates from methodologically heterogeneous post-marketing observational research primarily based on registries, potential cohorts, and giant digital well being databases.

Dbndd1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL504707 Origene Technologies GmbH 5 µg/vial Ask for price

Dbndd2 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL703783 Origene Technologies GmbH 5 µg/vial Ask for price

DBNDD2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL305099 Origene Technologies GmbH 5 µg/vial Ask for price

Dbndd2 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector

TL502919 Origene Technologies GmbH 5 µg/vial Ask for price

Dbndd1 ORF Vector (Rat) (pORF)

ORF065791 ABM 1.0 ug DNA 607.2 EUR

DBNDD1 ORF Vector (Human) (pORF)

ORF018059 ABM 1.0 ug DNA 486 EUR

Dbndd1 ORF Vector (Mouse) (pORF)

ORF042642 ABM 1.0 ug DNA 607.2 EUR

Dbndd1 ORF Vector (Mouse) (pORF)

ORF042643 ABM 1.0 ug DNA 607.2 EUR

Dbndd1 ORF Vector (Mouse) (pORF)

ORF042644 ABM 1.0 ug DNA 607.2 EUR

DBNDD1 Protein Vector (Rat) (pPM-C-HA)

PV263164 ABM 500 ng 723.6 EUR

DBNDD1 Protein Vector (Rat) (pPB-C-His)

PV263162 ABM 500 ng 723.6 EUR

DBNDD1 Protein Vector (Rat) (pPB-N-His)

PV263163 ABM 500 ng 723.6 EUR

DBNDD1 Protein Vector (Rat) (pPM-C-His)

PV263165 ABM 500 ng 723.6 EUR

DBNDD1 Protein Vector (Human) (pPM-C-HA)

PV072235 ABM 500 ng 662.4 EUR

DBNDD1 Protein Vector (Mouse) (pPM-C-HA)

PV170568 ABM 500 ng 723.6 EUR

DBNDD1 Protein Vector (Mouse) (pPM-C-HA)

PV170572 ABM 500 ng 723.6 EUR

DBNDD1 Protein Vector (Mouse) (pPM-C-HA)

PV170576 ABM 500 ng 723.6 EUR

DBNDD1 Protein Vector (Human) (pPB-C-His)

PV072233 ABM 500 ng 662.4 EUR

DBNDD1 Protein Vector (Human) (pPB-N-His)

PV072234 ABM 500 ng 662.4 EUR

DBNDD1 Protein Vector (Human) (pPM-C-His)

PV072236 ABM 500 ng 662.4 EUR

DBNDD1 Protein Vector (Mouse) (pPB-C-His)

PV170566 ABM 500 ng 723.6 EUR

DBNDD1 Protein Vector (Mouse) (pPB-N-His)

PV170567 ABM 500 ng 723.6 EUR

DBNDD1 Protein Vector (Mouse) (pPM-C-His)

PV170569 ABM 500 ng 723.6 EUR

DBNDD1 Protein Vector (Mouse) (pPB-C-His)

PV170570 ABM 500 ng 723.6 EUR

DBNDD1 Protein Vector (Mouse) (pPB-N-His)

PV170571 ABM 500 ng 723.6 EUR

DBNDD1 Protein Vector (Mouse) (pPM-C-His)

PV170573 ABM 500 ng 723.6 EUR

DBNDD1 Protein Vector (Mouse) (pPB-C-His)

PV170574 ABM 500 ng 723.6 EUR

DBNDD1 Protein Vector (Mouse) (pPB-N-His)

PV170575 ABM 500 ng 723.6 EUR

DBNDD1 Protein Vector (Mouse) (pPM-C-His)

PV170577 ABM 500 ng 723.6 EUR

Dbndd1 - Rat shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

TL702279V Origene Technologies GmbH 500 ul each Ask for price

DBNDD1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

TL317446V Origene Technologies GmbH 500 ul each Ask for price

Dbndd1 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

TL504707V Origene Technologies GmbH 500 ul each Ask for price

DBNDD1

pro-1162 ProSpec Tany 5µg 60 EUR
Description: Recombinant Human Dysbindin (Dystrobrevin Binding Protein 1) Domain Containing 1

Dbndd1 sgRNA CRISPR Lentivector set (Rat)

K6273401 ABM 3 x 1.0 ug 406.8 EUR

DBNDD1 sgRNA CRISPR Lentivector set (Human)

K0563301 ABM 3 x 1.0 ug 406.8 EUR

Dbndd1 sgRNA CRISPR Lentivector set (Mouse)

K3858501 ABM 3 x 1.0 ug 406.8 EUR

Dbndd1 - Rat, 4 unique 29mer shRNA constructs in retroviral untagged vector

TR702279 Origene Technologies GmbH 5 µg/vial Ask for price

Dbndd1 sgRNA CRISPR Lentivector (Rat) (Target 1)

K6273402 ABM 1.0 ug DNA 184.8 EUR

Dbndd1 sgRNA CRISPR Lentivector (Rat) (Target 2)

K6273403 ABM 1.0 ug DNA 184.8 EUR

Dbndd1 sgRNA CRISPR Lentivector (Rat) (Target 3)

K6273404 ABM 1.0 ug DNA 184.8 EUR

DBNDD1 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector

TR317446 Origene Technologies GmbH 5 µg/vial Ask for price

Dbndd1 - Mouse, 4 unique 29mer shRNA constructs in retroviral untagged vector

TR504707 Origene Technologies GmbH 5 µg/vial Ask for price

DBNDD1 siRNA

20-abx913603 Abbexa
  • Ask for price
  • Ask for price
  • 15 nmol
  • 30 nmol

DBNDD1 siRNA

20-abx913604 Abbexa
  • Ask for price
  • Ask for price
  • 15 nmol
  • 30 nmol

DBNDD1 siRNA

20-abx901417 Abbexa
  • Ask for price
  • Ask for price
  • 15 nmol
  • 30 nmol

DBNDD1 sgRNA CRISPR Lentivector (Human) (Target 1)

K0563302 ABM 1.0 ug DNA 184.8 EUR

DBNDD1 sgRNA CRISPR Lentivector (Human) (Target 2)

K0563303 ABM 1.0 ug DNA 184.8 EUR

DBNDD1 sgRNA CRISPR Lentivector (Human) (Target 3)

K0563304 ABM 1.0 ug DNA 184.8 EUR

Dbndd1 sgRNA CRISPR Lentivector (Mouse) (Target 1)

K3858502 ABM 1.0 ug DNA 184.8 EUR

Dbndd1 sgRNA CRISPR Lentivector (Mouse) (Target 2)

K3858503 ABM 1.0 ug DNA 184.8 EUR

Dbndd1 sgRNA CRISPR Lentivector (Mouse) (Target 3)

K3858504 ABM 1.0 ug DNA 184.8 EUR

DBNDD1 Protein

20-abx260921 Abbexa
  • Ask for price
  • Ask for price
  • Ask for price
  • 1 mg
  • 20 ug
  • 5 ug

DBNDD1 Protein

abx260921-10g Abbexa 10 µg 325 EUR

DBNDD1 Protein

abx260921-2g Abbexa 2 µg 225 EUR

DBNDD1 siRNA (Rat)

MBS8220215-15nmol MyBiosource 15nmol 405 EUR

DBNDD1 siRNA (Rat)

MBS8220215-30nmol MyBiosource 30nmol 565 EUR

DBNDD1 siRNA (Rat)

MBS8220215-5x30nmol MyBiosource 5x30nmol 2450 EUR

DBNDD1 siRNA (Mouse)

MBS8231446-15nmol MyBiosource 15nmol 405 EUR

DBNDD1 siRNA (Mouse)

MBS8231446-30nmol MyBiosource 30nmol 565 EUR

DBNDD1 siRNA (Mouse)

MBS8231446-5x30nmol MyBiosource 5x30nmol 2450 EUR

DBNDD1 siRNA (Human)

MBS8232890-15nmol MyBiosource 15nmol 405 EUR

DBNDD1 siRNA (Human)

MBS8232890-30nmol MyBiosource 30nmol 565 EUR

DBNDD1 siRNA (Human)

MBS8232890-5x30nmol MyBiosource 5x30nmol 2450 EUR

Human DBNDD1 Antibody

33409-05111 AssayPro 150 ug 215 EUR

Recombinant Human DBNDD1

MBS7611380-005mg MyBiosource 0.05mg 345 EUR

Recombinant Human DBNDD1

MBS7611380-02mg MyBiosource 0.2mg 635 EUR

Recombinant Human DBNDD1

MBS7611380-1mg MyBiosource 1mg 1800 EUR

Recombinant Human DBNDD1

MBS7611380-5x1mg MyBiosource 5x1mg 6955 EUR

Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat)

K6273405 ABM 3 x 1.0 ug 451.2 EUR

DBNDD1 Polyclonal Antibody

MBS9235031-01mL MyBiosource 0.1mL 415 EUR

DBNDD1 Polyclonal Antibody

MBS9235031-5x01mL MyBiosource 5x0.1mL 1841 EUR

DBNDD1 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)

K0563305 ABM 3 x 1.0 ug 451.2 EUR

Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse)

K3858505 ABM 3 x 1.0 ug 451.2 EUR

Rat Dbndd1 ELISA Kit

ELI-46842r Nova Lifetech 96tests 756 EUR

DBNDD1 protein (His tag)

80R-2386 Fitzgerald 100 ug 329 EUR
Description: Purified recombinant Human DBNDD1 protein (His tag)

Rat DBNDD1 shRNA Plasmid

20-abx990198 Abbexa
  • Ask for price
  • Ask for price
  • 150 µg
  • 300 µg

Lenti ORF clone of Dbndd1 (mGFP-tagged ORF) - Rat dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), (10 ug)

RR206226L4 Origene Technologies GmbH 10 µg Ask for price

Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1)

K6273406 ABM 1.0 ug DNA 200.4 EUR

Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2)

K6273407 ABM 1.0 ug DNA 200.4 EUR

Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3)

K6273408 ABM 1.0 ug DNA 200.4 EUR

Mouse DBNDD1 shRNA Plasmid

20-abx977710 Abbexa
  • Ask for price
  • Ask for price
  • 150 µg
  • 300 µg

Human DBNDD1 shRNA Plasmid

20-abx962250 Abbexa
  • Ask for price
  • Ask for price
  • 150 µg
  • 300 µg

Lenti ORF particles, Dbndd1 (GFP-tagged ORF) - Rat dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), 200ul, >10^7 TU/mL

RR206226L4V Origene Technologies GmbH 200 µl Ask for price

Human DBNDD1 Protein Lysate

MBS8410297-002mg MyBiosource 0.02mg 365 EUR

Human DBNDD1 Protein Lysate

MBS8410297-5x002mg MyBiosource 5x0.02mg 1410 EUR

Lenti ORF clone of Dbndd1 (Myc-DDK-tagged ORF) - Rat dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), (10 ug)

RR206226L3 Origene Technologies GmbH 10 µg Ask for price

DBNDD1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1)

K0563306 ABM 1.0 ug DNA 200.4 EUR

DBNDD1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2)

K0563307 ABM 1.0 ug DNA 200.4 EUR

DBNDD1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3)

K0563308 ABM 1.0 ug DNA 200.4 EUR

Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1)

K3858506 ABM 1.0 ug DNA 200.4 EUR

Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2)

K3858507 ABM 1.0 ug DNA 200.4 EUR

Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3)

K3858508 ABM 1.0 ug DNA 200.4 EUR

Dbndd2 - Rat shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

TL703783V Origene Technologies GmbH 500 ul each Ask for price

DBNDD1 Recombinant Protein (Rat)

RP197369 ABM 100 ug Ask for price

Lenti ORF particles, DBNDD1 (Myc-DDK tagged) - Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant

RC200971L3V Origene Technologies GmbH 200 µl Ask for price

Lenti ORF particles, DBNDD1 (mGFP-tagged) - Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant 2,

RC200971L4V Origene Technologies GmbH 200 µl Ask for price

Lenti ORF particles, DBNDD1 (Myc-DDK tagged) - Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant

RC212789L3V Origene Technologies GmbH 200 µl Ask for price

Lenti ORF particles, DBNDD1 (mGFP-tagged) - Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant 1,

RC212789L4V Origene Technologies GmbH 200 µl Ask for price

Lenti ORF clone of Dbndd1 (mGFP-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 3

MR217937L4 Origene Technologies GmbH 10 µg Ask for price

Lenti ORF clone of Dbndd1 (mGFP-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 1

MR216430L4 Origene Technologies GmbH 10 µg Ask for price

Lenti ORF clone of Dbndd1 (mGFP-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 2

MR216440L4 Origene Technologies GmbH 10 µg Ask for price

DBNDD1 Recombinant Protein (Human)

RP054174 ABM 100 ug Ask for price

DBNDD1 Recombinant Protein (Mouse)

RP127922 ABM 100 ug Ask for price

DBNDD1 Recombinant Protein (Mouse)

RP127925 ABM 100 ug Ask for price

DBNDD1 Recombinant Protein (Mouse)

RP127928 ABM 100 ug Ask for price

Lenti ORF particles, Dbndd1 (Myc-DDK-tagged ORF) - Rat dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), 200ul, >10^7 TU/m

RR206226L3V Origene Technologies GmbH 200 µl Ask for price

Lenti ORF particles, Dbndd1 (Myc-DDK-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant

MR217937L3V Origene Technologies GmbH 200 µl Ask for price

Lenti ORF particles, Dbndd1 (Myc-DDK-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant

MR216430L3V Origene Technologies GmbH 200 µl Ask for price

Lenti ORF particles, Dbndd1 (Myc-DDK-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant

MR216440L3V Origene Technologies GmbH 200 µl Ask for price

DBNDD2 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

TL305099V Origene Technologies GmbH 500 ul each Ask for price

Dbndd2 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

TL502919V Origene Technologies GmbH 500 ul each Ask for price

Lenti ORF particles, Dbndd1 (GFP-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 3, 2

MR217937L4V Origene Technologies GmbH 200 µl Ask for price

Lenti ORF particles, Dbndd1 (GFP-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 1, 2

MR216430L4V Origene Technologies GmbH 200 µl Ask for price

Lenti ORF particles, Dbndd1 (GFP-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 2, 2

MR216440L4V Origene Technologies GmbH 200 µl Ask for price

Lenti ORF clone of Dbndd1 (Myc-DDK-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 3

MR217937L3 Origene Technologies GmbH 10 µg Ask for price

Lenti ORF clone of Dbndd1 (Myc-DDK-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 1

MR216430L3 Origene Technologies GmbH 10 µg Ask for price

Lenti ORF clone of Dbndd1 (Myc-DDK-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 2

MR216440L3 Origene Technologies GmbH 10 µg Ask for price

Human DBNDD1 knockout cell line

ABC-KH3951 AcceGen 1 vial Ask for price
Description: Human DBNDD1 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology.

DBNDD1 (NM_001042610) Human Over-expression Lysate

LS079007 BosterBio 100ug 628 EUR
Description: Transient overexpression lysate of dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant 1

Human DBNDD1 knockdown cell line

ABC-KD3951 AcceGen 1 vial Ask for price
Description: Human DBNDD1 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest.

Human DBNDD1 Protein Lysate 20ug

IHUDBNDD1PLLY20UG Innovative research each 213 EUR
Description: Human DBNDD1 Protein Lysate 20ug

Recombinant Human DBNDD1, GST-tagged

DBNDD1-11844H Creative BioMart 25ug 255.2 EUR
Description: The protein is stored in PBS buffer at -20℃. Avoid repeated freezing and thawing cycles.

Human DBNDD1 Antibody (Biotin Conjugate)

33409-05121 AssayPro 150 ug 315 EUR

OCOA15211-20UG - DBNDD1 Protein Lysate

OCOA15211-20UG Aviva Systems Biology 20ug 169 EUR

OCOA08431-20UG - DBNDD1 Protein Lysate

OCOA08431-20UG Aviva Systems Biology 20ug 169 EUR

Dbndd1 (untagged ORF) - Rat dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), (10 ug)

RN206226 Origene Technologies GmbH 10 µg Ask for price

DBNDD1 Over-expression Lysate Product

GWB-7044A5 GenWay Biotech 0.1 mg Ask for price

DBNDD1, 1-158aa, Human, His tag, E Coli

MBS204279-002mg MyBiosource 0.02mg 215 EUR

DBNDD1, 1-158aa, Human, His tag, E Coli

MBS204279-01mg MyBiosource 0.1mg 340 EUR

DBNDD1, 1-158aa, Human, His tag, E Coli

MBS204279-05mg MyBiosource 0.5mg 765 EUR

DBNDD1, 1-158aa, Human, His tag, E Coli

MBS204279-5x05mg MyBiosource 5x0.5mg 3195 EUR

DBNDD1 (untagged)-Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant 2

SC321574 Origene Technologies GmbH 10 µg Ask for price

DBNDD1 (untagged) - Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant 3

SC334042 Origene Technologies GmbH 10 µg Ask for price

DBNDD1 (untagged) - Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant 4

SC335014 Origene Technologies GmbH 10 µg Ask for price

DBNDD1 (untagged)-Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant 1

SC311345 Origene Technologies GmbH 10 µg Ask for price

DBNDD1 3'UTR GFP Stable Cell Line

TU055580 ABM 1.0 ml 1672.8 EUR

Dbndd1 3'UTR GFP Stable Cell Line

TU253166 ABM 1.0 ml Ask for price

Dbndd1 3'UTR GFP Stable Cell Line

TU154864 ABM 1.0 ml Ask for price

Dbndd2 ORF Vector (Rat) (pORF)

ORF065792 ABM 1.0 ug DNA 607.2 EUR

Dbndd1 (Myc-DDK-tagged ORF) - Rat dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), (10 ug)

RR206226 Origene Technologies GmbH 10 µg Ask for price

Dbndd2 ORF Vector (Mouse) (pORF)

ORF042645 ABM 1.0 ug DNA 607.2 EUR

Dbndd2 ORF Vector (Mouse) (pORF)

ORF042646 ABM 1.0 ug DNA 607.2 EUR

Dbndd2 ORF Vector (Mouse) (pORF)

ORF042647 ABM 1.0 ug DNA 607.2 EUR

Dbndd2 ORF Vector (Mouse) (pORF)

ORF042648 ABM 1.0 ug DNA 607.2 EUR

DBNDD2 ORF Vector (Human) (pORF)

ORF002929 ABM 1.0 ug DNA 114 EUR

Dbndd1 (untagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 1, (10ug)

MC211300 Origene Technologies GmbH 10 µg Ask for price

Dbndd1 (untagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 2, (10ug)

MC211301 Origene Technologies GmbH 10 µg Ask for price

Dbndd1 (untagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 3, (10ug)

MC211302 Origene Technologies GmbH 10 µg Ask for price

DBNDD1 (GFP-tagged) - Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant 1

RG212789 Origene Technologies GmbH 10 µg Ask for price

DBNDD1 (GFP-tagged) - Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant 2

RG200971 Origene Technologies GmbH 10 µg Ask for price

DBNDD1 3'UTR Luciferase Stable Cell Line

TU005580 ABM 1.0 ml 1672.8 EUR

Dbndd1 3'UTR Luciferase Stable Cell Line

TU203166 ABM 1.0 ml Ask for price

Dbndd1 3'UTR Luciferase Stable Cell Line

TU104864 ABM 1.0 ml Ask for price

Dbndd1 (Myc-DDK-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 3

MR217937 Origene Technologies GmbH 10 µg Ask for price

Dbndd1 (Myc-DDK-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 1

MR216430 Origene Technologies GmbH 10 µg Ask for price

Dbndd1 (Myc-DDK-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1), transcript variant 2

MR216440 Origene Technologies GmbH 10 µg Ask for price

Dbndd1 (GFP-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1) transcript variant 1, (10ug)

MG216430 Origene Technologies GmbH 10 µg Ask for price

Dbndd1 (GFP-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1) transcript variant 2, (10ug)

MG216440 Origene Technologies GmbH 10 µg Ask for price

Dbndd1 (GFP-tagged) - Mouse dysbindin (dystrobrevin binding protein 1) domain containing 1 (Dbndd1) transcript variant 3, (10ug)

MG217937 Origene Technologies GmbH 10 µg Ask for price

DBNDD1 (Myc-DDK-tagged)-Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant 2

RC200971 Origene Technologies GmbH 10 µg Ask for price

DBNDD1 (Myc-DDK-tagged)-Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant 1

RC212789 Origene Technologies GmbH 10 µg Ask for price

DBNDD1 (myc-DDK-tagged) - Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant 3

RC236148 Origene Technologies GmbH 10 µg Ask for price

DBNDD1 (myc-DDK-tagged) - Human dysbindin (dystrobrevin binding protein 1) domain containing 1 (DBNDD1), transcript variant 4

RC237120 Origene Technologies GmbH 10 µg Ask for price

DBN1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

LV660313 ABM 1.0 ug DNA 1626 EUR

DBN1 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV660317 ABM 1.0 ug DNA 1626 EUR

Recombinant Human DBNDD1 Protein, His, E.coli-1mg

QP11597-1mg EnQuireBio 1mg 3308.4 EUR

Recombinant Human DBNDD1 Protein, His, E.coli-5ug

QP11597-5ug EnQuireBio 5ug 186 EUR

Human DBNDD1 AssayLite™ Antibody (RPE Conjugate)

33409-05151 AssayPro 150 ug 370 EUR

Human DBNDD1 AssayLite™ Antibody (APC Conjugate)

33409-05161 AssayPro 150 ug 370 EUR

Recombinant Human DBNDD1 Protein, His, E.coli-20ug

QP11597-20ug EnQuireBio 20ug 241.2 EUR

DBNDD2 Protein Vector (Rat) (pPM-C-HA)

PV263168 ABM 500 ng 723.6 EUR

DBN1 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV660318 ABM 1.0 ug DNA 1626 EUR

Human DBNDD1 AssayLite™ Antibody (FITC Conjugate)

33409-05141 AssayPro 150 ug 370 EUR

DBNDD2 Protein Vector (Rat) (pPB-C-His)

PV263166 ABM 500 ng 723.6 EUR

DBNDD2 Protein Vector (Rat) (pPB-N-His)

PV263167 ABM 500 ng 723.6 EUR

DBNDD2 Protein Vector (Rat) (pPM-C-His)

PV263169 ABM 500 ng 723.6 EUR

Human DBNDD1 AssayLite™ Antibody (PerCP Conjugate)

33409-05171 AssayPro 150 ug 410 EUR

DBNDD2 Protein Vector (Human) (pPM-C-HA)

PV011715 ABM 500 ng 394.8 EUR

DBNDD2 Protein Vector (Mouse) (pPM-C-HA)

PV170580 ABM 500 ng 723.6 EUR

DBNDD2 Protein Vector (Mouse) (pPM-C-HA)

PV170584 ABM 500 ng 723.6 EUR

DBNDD2 Protein Vector (Mouse) (pPM-C-HA)

PV170588 ABM 500 ng 723.6 EUR

DBNDD2 Protein Vector (Mouse) (pPM-C-HA)

PV170592 ABM 500 ng 723.6 EUR

DBNDD2 Protein Vector (Human) (pPB-C-His)

PV011713 ABM 500 ng 394.8 EUR

DBNDD2 Protein Vector (Human) (pPB-N-His)

PV011714 ABM 500 ng 394.8 EUR

DBNDD2 Protein Vector (Human) (pPM-C-His)

PV011716 ABM 500 ng 394.8 EUR

DBNDD2 Protein Vector (Mouse) (pPB-C-His)

PV170578 ABM 500 ng 723.6 EUR

DBNDD2 Protein Vector (Mouse) (pPB-N-His)

PV170579 ABM 500 ng 723.6 EUR

DBNDD2 Protein Vector (Mouse) (pPM-C-His)

PV170581 ABM 500 ng 723.6 EUR
Is has been clearly demonstrated that valproate is related to a excessive danger of CM/NDD, whereas lamotrigine and levetiracetam are comparatively secure. However, proof is much less express for different ASM. Reported dangers differ relying on the measurement and origin of the underlying examine inhabitants, the definition of publicity and outcomes, and different features of the examine design. Increased collaboration between information sources to extend pattern measurement are fascinating.
Back to top